Tyra Biosciences released Phase 2 data for dabogratinib, targeting bladder cancer, aiming to rival J&J's Balversa, with a 60mg dose showing 57% complete response rate.
Todd Harris, Tyra Biosciences CEO
September 9, 2026 07:00 AM EDT
Tyra finds ray of sunshine in otherwise cloudy Phase 2 bladder cancer data
Max Gelman
Tyra Biosciences wants to challenge Johnson & Johnson in a low-risk form of bladder cancer. The Phase 2 data it released Wednesday takes a step …
Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company…
Tyra Biosciences has | Tyra Biosciences has partnered with a patient advocacy group to create an awareness day for upper tract…
Tyra Biosciences stock fell sharply as initial dabogratinib Phase 2 data showed a 57% complete response rate at 60 mg.
The game is on for TROP2 antibody-drug conjugates in first-line triple-negative breast cancer. | Less than a month after an…
With a new phase 3 win for Erleada (apalutamide), Johnson & Johnson is proposing a solution to a longstanding prostate cancer…
Johnson & Johnson has unveiled massive phase 3 survival data for its dual bispecific combination in earlier-line multiple…
